Vyleesi injection is an FDA-approved bremelanotide autoinjector for HSDD in premenopausal women. Learn how it works, dosing, side effects, cost, and more.
Vyleesi injection is an FDA-approved subcutaneous autoinjector that delivers 1.75 mg of bremelanotide for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The label allows no more than one dose in 24 hours and no more than eight doses per month.
What Vyleesi Is and Who It Is For
Vyleesi is a prescription medicine for premenopausal women whose low sexual desire causes marked distress or interpersonal difficulty and is not explained by a medical condition, a psychiatric condition, relationship problems, or another medication. A clinician makes that determination, and the drug is not intended as a general libido enhancer.
Bremelanotide is not a hormone. It is a melanocortin receptor agonist, and researchers believe it acts on central nervous system pathways that influence desire rather than on estrogen or testosterone levels.
FDA approval covers premenopausal women only. Vyleesi is not approved for postmenopausal women, and it is not a treatment for erectile dysfunction in men. It is also a brand-name product, so any search for vyleesi generic leads back to the manufacturer or to unregulated products that are not equivalents.
How to Use Vyleesi: Instructions Step by Step
The autoinjector is a single-use device, so the process is short. Follow the instructions printed in the carton along with your prescriber's directions.
- Wash your hands and choose an injection site on the front of your thigh or on your abdomen.
- Avoid the two-inch area around the navel, and skip skin that is scarred, tender, bruised, or irritated.
- Press the autoinjector against clean, dry skin at a 90-degree angle and trigger the injection as shown in the device instructions.
- Hold the device in place for the recommended time, then remove it and confirm that the dose was delivered.
- Rotate injection sites between doses, and dispose of the used device in a sharps container.
Timing matters more than technique for most users. The dose should go in at least 45 minutes before you expect sexual activity, and it should never be repeated within the same 24-hour period.
Dosing limits
Eight doses per month is the ceiling, no matter how the days fall. If you have not noticed any improvement after eight weeks of use, the label advises stopping the medication rather than continuing indefinitely.
Vyleesi Side Effects and Safety Considerations
Nausea is the most commonly reported reaction, followed by flushing, headache, and injection-site reactions such as stinging, redness, or swelling. Nausea is usually mild to moderate and often short-lived.
Two safety issues deserve more attention than the rest.
- Blood pressure. Vyleesi can cause a temporary rise in blood pressure and a small drop in heart rate. It is contraindicated in women with uncontrolled hypertension or known cardiovascular disease, and clinicians typically check blood pressure before prescribing.
- Hyperpigmentation. Darkening of the skin, gums, and other areas has been reported, including after short-term use. This effect may not fade once the medication is stopped.
Alcohol is not prohibited by the label, but it can make nausea worse. Tell your prescriber about every medication you take and about any history of heart or blood pressure problems before starting treatment.
Anyone weighing the trade-offs should read the full prescribing information and discuss vyleesi side effects with a healthcare professional instead of relying on forum posts alone.
Vyleesi vs Addyi and Other Prescription Options
Vyleesi and Addyi are the two FDA-approved medications for HSDD, and they work in completely different ways.
| Feature | Vyleesi (bremelanotide) | Addyi (flibanserin) |
|---|---|---|
| FDA approval | 2019 | 2015 |
| Form | Subcutaneous autoinjector | Oral tablet |
| How it is taken | As needed, at least 45 minutes before sex | Once nightly at bedtime, every day |
| Monthly limit | Up to 8 doses | Daily use; no as-needed dosing |
| Common side effects | Nausea, flushing, headache, injection-site reactions | Dizziness, sleepiness, nausea, fatigue |
| Notable warnings | Transient blood pressure increase; skin and gum darkening | Low blood pressure and fainting; alcohol restriction |
| Approved population | Premenopausal women with acquired, generalized HSDD | Premenopausal women with acquired, generalized HSDD |
The practical difference is scheduling. Vyleesi is used on demand, while Addyi is a nightly pill that has to be taken consistently to have any chance of working. Addyi also carries a label restriction on alcohol within two hours of a dose because of fainting risk; Vyleesi does not have that specific restriction.
Neither drug works for everyone. In clinical trials, both produced modest average improvements in desire and distress compared with placebo, which is why many women weigh vyleesi vs addyi and other options with their clinician before deciding.
Bremelanotide, PT-141, and Research Peptides
Bremelanotide is the same molecule that research communities call PT-141. That overlap has created a gray market of "research use only" peptide powders sold in vials with labels stating they are not for human consumption. Those products are not FDA-approved, are not made under pharmaceutical manufacturing standards, and their purity and sterility are not verified by any regulator.
The original clinical development program tested a nasal formulation. Absorption through the nose was variable and blood pressure effects were a concern, so the approved product ended up as an injection. That history explains why searches for pt-141 nasal spray vs injection are common, but only the subcutaneous autoinjector carries an approved label.
Guessing a dose from a powder weight is not the same as using a standardized 1.75 mg autoinjector, and the safety profile of an unregulated product is unknown.
Cost, Insurance, and Generic Availability
List pricing for the autoinjector has been reported in the range of about $99 per dose, and manufacturer savings programs have at times lowered out-of-pocket costs for eligible patients. Insurance coverage varies widely, and some plans require prior authorization or step therapy before they will pay.
Because no FDA-approved generic bremelanotide exists in the United States, vyleesi cost is driven by brand pricing, plan design, and any copay support you qualify for. Addyi is likewise brand only.
Before assuming vyleesi cost is out of reach, check your formulary and ask about the manufacturer copay card. Pharmacy staff or your prescriber's office can usually run a benefits check and give you a real number the same day.
Low sexual desire has many possible causes, so a prescription is one part of a broader conversation with a healthcare professional about hormones, medications, mental health, and relationships.
Frequently Asked Questions
How long before sex should you inject Vyleesi?
Vyleesi should be injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The dose is 1.75 mg from a single-use autoinjector, and it must not be repeated within 24 hours or used more than eight times per month. Some women notice a difference early on, while others need several uses to judge whether it helps.
Does insurance cover Vyleesi?
Coverage depends on the plan. Many commercial plans cover Vyleesi with prior authorization, and the manufacturer offers a savings program that can reduce out-of-pocket costs for eligible patients. Because there is no FDA-approved generic version, paying cash can be expensive.
Is Vyleesi the same as PT-141?
Yes. Bremelanotide is the molecule studied under the research name PT-141, and Vyleesi is the FDA-approved brand-name autoinjector. Research-grade PT-141 powders sold online are not approved for human use and are not manufactured to pharmaceutical quality standards.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.